Methods of administering mesenchymal stem cells activated by cytokines for enhancing immunosuppression
AssigneeRutgers, The State University of New Jersey
InventorsYufang Shi, Guangwen Ren, Liying Zhang
Life of this patent
Estimating the term…
Abstract
The present invention provides methods or kits with inflammatory cytokines to pretreat 1-ISCs to augment their immune modulatory effect, in prevention and treatment of various diseases such as multiple sclerosis, arthritis, lupus, sepsis, hepatitis, cirrhosis, Parkinson's disease, chronic infections, and GvHD. The present invention relates to novel methods for enhancing the immunosuppressive or the immune stimulatory activities of mesenchymal stem cells (JvfSCs).
Claims8
A method for enhancing immunosuppression of an immune response mediated by activated T cells in a patient in need thereof comprising administering to said patient an effective amount of:
- (a) a population of isolated mesenchymal stem cells activated by culturing in a medium comprising interferon gamma (IFNγ), interleukin 17A (IL-17A), and tumor necrosis factor alpha (TNF α);
- (b) isolated IFNγ;
- (c) TNF α;
- and
- (d) IL-17A.
A method of suppressing an immune response mediated by activated T cells comprising administering to a subject in need thereof an effective amount of a population of isolated mesenchymal stem cells prepared by a process comprising the steps of:
- (i) obtaining multipotent progenitor cells;
- (ii) culturing said multipotent progenitor cells in a medium;
- (iii) separating mesenchymal stem cells from differentiated cells in said medium;
- and
- (iv) activating at least a subset of said separated mesenchymal stem cells by culturing the cells in a medium comprising isolated interferon gamma (IFNγ), interleukin 17A (IL-17A), and tumor necrosis factor alpha (TNF α), for a sufficient period of time such that the activated mesenchymal stem cells are immunosuppressive.
A method for suppressing an immune response mediated by activated T cells in a patient in need thereof comprising administering to said patient a composition comprising an effective amount of a population of isolated mesenchymal stem cells activated by culturing in a medium comprising interferon gamma (IFNγ), interleukin 17A (IL-17A), and tumor necrosis factor alpha (TNF α) for a sufficient amount of time.
Dependencies are inferred from the claim text.